Vera Therapeutics VERA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$121.03M-134% | -$91.1M-110% | -$80.29M-72.2% | -$76.53M-127% | -$51.69M-82.1% | ||
| $140K+64.7% | $135K+145% | $129K+438% | $119K+693% | $85K+673% | ||
| $13.21M+70.6% | $10.97M+76.4% | $9.75M+74.4% | $9.47M+94.4% | $7.74M+87.8% | ||
| -$7.97M-599% | $3.63M— | $4.79M+7,831% | $3.9M+815% | $1.6M+127% | ||
| -$437K+90.9% | $7.21M— | $3.92M-51.5% | $8.1M+76.9% | -$4.78M-183% | ||
| $5.14M-12.5% | $372K+175% | —— | —— | $5.88M+1,399% | ||
| $116K-74.6% | $113K-79.4% | $435K-12.3% | $444K-11.7% | $457K-11.6% | ||
| -$182K+53.8% | -$100K+81.1% | -$520K+15.9% | -$469K+24.7% | -$394K+38.1% | ||
| $0+100% | -$1K+88.9% | —— | -$141K-985% | -$17K-88.9% | ||
| -$106.5M-95.8% | -$69.99M-78.6% | -$61.91M-67.8% | -$54.8M-121% | -$54.41M-60.8% | ||
| $23K-87.7% | $102K-84.2% | $133K-44.1% | $208K+134% | $187K— | ||
| -$137.82M-1,000% | $80.66M+136% | $69.76M— | $28.54M+226% | $15.32M+107% | ||
| —— | $0-100% | —— | —— | —— | ||
| $3.94M+157% | $4.19M+81.2% | $797K+6.0% | $464K-86.5% | $1.53M-77.8% | ||
| $3.94M+157% | $286.28M-12.2% | $797K+7.8% | $20.29M+490% | $1.53M-99.4% | ||
| -$240.37M-540% | $296.95M+354% | $8.65M+299% | -$5.97M+86.4% | -$37.56M-260% | ||
| $1.63M+3.2% | $1.72M+3.2% | $1.77M+1.7% | $1.66M-4.4% | $1.58M+4.0% | ||
| -$843K+66.7% | —— | —— | —— | -$2.53M-51.6% | ||
| $639K+189% | —— | —— | —— | $221K+16.9% | ||
| -$182K+53.8% | -$100K+81.1% | -$520K+15.9% | -$469K+24.7% | -$394K+38.1% | ||
| $0+100% | -$1K+88.9% | —— | -$141K-985% | -$17K-88.9% | ||
| $5.14M-12.5% | $372K+175% | —— | —— | $5.88M+1,399% | ||
| $116K-74.6% | $113K-79.4% | $435K-12.3% | $444K-11.7% | $457K-11.6% | ||
| $15M+1,900% | —— | —— | —— | $750K— | ||
| $150K— | —— | —— | —— | $0— | ||
| $15M+1,900% | —— | —— | —— | $750K— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $3.94M+157% | $4.19M+81.2% | $797K+6.0% | $464K-86.5% | $1.53M-77.8% | ||
| $188K-70.3% | —— | —— | —— | $634K— | ||
| -$182K+53.8% | -$100K+81.1% | -$520K+15.9% | -$469K+24.7% | -$394K+38.1% | ||
| —— | $63K— | $63K— | $63K— | $63K— | ||
| $193K— | —— | —— | —— | $0-100% | ||
| -$106.52M-95.1% | -$70.1M-76.0% | -$62.04M-67.1% | -$55.01M-121% | -$54.59M-61.4% | ||
| -$106.52M-95.1% | -$70.1M-76.0% | -$62.04M-67.1% | -$55.01M-121% | -$54.59M-61.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vera Therapeutics generate?
- Vera Therapeutics (VERA) generated -$293.2M in operating cash flow over the trailing twelve months.
- What is Vera Therapeutics's free cash flow?
- After $466.0K of capital expenditures, Vera Therapeutics's free cash flow was -$293.7M over the trailing twelve months, down 87.8% year over year.
- Where does Vera Therapeutics's cash flow data come from?
- Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.